A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia
Principal Investigator
Ging-Yuek Robin HsiungOverview
Study Start/End
May 11, 2018 to Dec 31, 2019Locations
UBC HospitalName/Title
Eloise Nicklin, Clinical Trials CoordinatorPhone
604-822-0324Email Address
eloise.nicklin@vch.caPurpose of Study
The purpose of this study is to assess the safety, tolerability and effects on behaviour of Syntocinon given intranasally (by a spray into the nostrils) compared to placebo (an inactive saline substance that contains no medication) in participants with frontotemporal dementia/Pick's disease.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.